| Media Room :: Press Releases

search the site...

Company Info		Media Room		Financial Info		Research		Products

Fact Sheet		Press Releases

topic:

page:

notify me about
updates

date				title / topic / summary	sort by topic

12/10/2009				Nymox Announces New $15 Million Equity Financing Commitment topic: Financial December 10, 2009: Nymox is pleased to announce that the Company has secured commitment for $15 million in equity financing from institutional investors.
11/23/2009				Nymox Releases Positive New Clinical Trial Data on Durability of Benefits for Early Responders to Company’s BPH Drug NX-1207 topic: R&D: BPH (enlarged prostate) Treatments November 23, 2009: Nymox announced today the release of positive new clinical trial data from responder analysis of the Company’s pooled multicenter U.S. Phase 2 studies of NX-1207, indicating durable early responder benefits from Nymox’s innovative drug treatment for benign prostatic hyperplasia (BPH).
11/13/2009				Nymox Reports Third Quarter 2009 Financial Results topic: Financial November 13, 2009: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the third quarter of 2009.
10/14/2009				Nymox's NX-1207 To Be Clinically Tested for Prostate Cancer topic: R&D: Cancer Treatments October 14, 2009: Nymox is pleased to announce that NX-1207, the Company's lead drug in development, has been shown to produce strongly positive and repeatable results in laboratory studies of human prostate cancer. In addition, local injection of NX-1207 showed activity in animals with transplanted human prostate carcinoma. The NX-1207 used in these studies is a different formulation and a much higher dosage from that of NX-1207 used to treat benign prostatic hyperplasia (BPH).
10/05/2009				Nymox Announces New Pooled Analysis Confirms 12 Month Benefit of NX-1207 Treatment for BPH topic: R&D: BPH (enlarged prostate) Treatments October 5, 2009: Nymox is pleased to announce that a new formal statistical analysis of double-blind clinical trial data from pooled subjects in Phase 2 clinical trials for NX-1207, the Company's investigational treatment for BPH, confirmed that clinically significant benefits of a single NX-1207 treatment extend to 12 months or longer.
08/26/2009				Nymox's NX-1207 Shows Major Effect on Liver Cancer topic: R&D: Cancer Treatments August 26, 2009: Nymox is pleased to announce that NX-1207, the Company's lead drug in development, has been shown to repeatedly produce strongly positive results when given to animals with hepatocellular carcinoma (HCC). In the experimental studies, the cancers were significantly reduced in size after 2 local injections of NX-1207. The rodents in the studies had transplanted human HCC, a standard model for cancer research. These animals had an average tumor burden reduction of close to 50% after 20 days. The NX-1207 used in these studies is a different formulation and a higher dosage from that of NX-1207 used to treat benign prostatic hyperplasia (BPH).
08/14/2009				Nymox Reports Second Quarter 2009 Financial Results topic: Financial August 14, 2009: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the second quarter of 2009.
06/02/2009				Nymox Announces Dosing of First Patient in Phase 3 Trial for NX-1207 for BPH topic: R&D: BPH (enlarged prostate) Treatments June 2, 2009: Nymox today announced the dosing of the first patient in the Company’s NX02-0017 multi-center, double-blind, placebo controlled Phase 3 U.S. clinical trial for NX-1207, the Company's investigational drug for the treatment of benign prostatic hyperplasia (BPH).
05/15/2009				Nymox Reports First Quarter 2009 Financial Results topic: Financial May 15, 2009: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the first quarter of 2009.
05/05/2009				Nymox Announces Start of Second Phase 3 Trial for NX-1207 for BPH topic: R&D: BPH (enlarged prostate) Treatments May 5, 2009: Nymox reported today that NX02-0018, the second Phase 3 U.S. clinical trial for NX-1207, the Company's investigational drug for BPH, has begun screening and enrolment of patients.